{"id":131090,"date":"2026-07-09T18:30:06","date_gmt":"2026-07-10T00:30:06","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=131090"},"modified":"2026-07-09T18:30:06","modified_gmt":"2026-07-10T00:30:06","slug":"triple-agonist-weight-loss-drugs-how-retatrutide-and-mazdutide-differ-from-glp-1s","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/triple-agonist-weight-loss-drugs-how-retatrutide-and-mazdutide-differ-from-glp-1s\/","title":{"rendered":"Triple-Agonist Weight Loss Drugs: How Retatrutide and Mazdutide Differ From GLP-1s"},"content":{"rendered":"

The newest weight-loss drugs work by hitting more hormone targets than GLP-1 alone, and the results suggest that more targets can mean more weight loss. Retatrutide is a true triple agonist (activating three receptors), while mazdutide adds one extra target to GLP-1. Both go beyond the single-pathway approach of drugs like Ozempic, and both add glucagon, a hormone that changes how the body burns energy. Retatrutide is investigational; mazdutide is approved in China but not by the FDA. Here’s how these multi-target drugs differ from GLP-1s.<\/p>\n

From One Target to Several<\/h3>\n

The first generation of these drugs (semaglutide, in Ozempic and Wegovy) activates a single receptor: GLP-1, which reduces appetite. The second generation added a second target: tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP, producing more weight loss. The newest drugs push further by adding glucagon and, in retatrutide’s case, a third pathway. The logic is that obesity involves multiple hormone systems, so engaging several at once may produce larger, more complete effects.<\/p>\n

What Each Hormone Adds<\/h3>\n

Here’s what the different targets do, which explains why adding them changes the results.<\/p>\n

\n\n\n\n\n\n\n\n
Hormone target<\/th>\nMain effect<\/th>\n<\/tr>\n<\/thead>\n
GLP-1<\/td>\nReduces appetite, slows stomach emptying<\/td>\n<\/tr>\n
GIP<\/td>\nEnhances weight loss and improves how the body handles nutrients<\/td>\n<\/tr>\n
Glucagon<\/td>\nIncreases energy expenditure (calorie burning), reduces liver fat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

The glucagon component is the interesting addition. On its own, glucagon raises blood sugar, but paired with GLP-1 (which lowers it), the net effect is favorable, and glucagon’s boost to calorie burning and liver-fat reduction adds a new dimension.<\/p>\n

Retatrutide: The Triple Agonist<\/h3>\n

Retatrutide is the headliner because it activates all three: GIP, GLP-1, and glucagon. This full triple approach has produced the largest weight loss of any drug in development. Its foundational phase 2 data, published in the New England Journal of Medicine<\/a> in 2023, showed about 24% weight loss at the highest dose, and later phase 3 results pushed toward 30%, approaching bariatric-surgery territory. That’s the payoff of engaging three pathways at once.<\/p>\n

Mazdutide: The Glucagon Dual Agonist<\/h3>\n

Mazdutide takes a different route. It’s a dual agonist activating GLP-1 and glucagon (but not GIP), based on a natural hormone called oxyntomodulin. Its glucagon component gives it a similar energy-burning and liver-fat benefit, and in trials it produced roughly 15% to 20% weight loss depending on dose. Notably, mazdutide is already approved in China, making it the first glucagon-containing weight-loss drug approved anywhere, though it’s not available in the US.<\/p>\n

Why This Matters and the Trade-Offs<\/h3>\n

Hitting more targets tends to produce more weight loss, but it can also mean more to monitor. Glucagon activity, for instance, can raise heart rate, and retatrutide’s higher doses come with a distinctive skin-tingling side effect. So the multi-target approach isn’t simply “more is better”; it’s a balance of greater efficacy against a broader set of effects to manage. Consider a hypothetical patient who hasn’t reached their goal on a GLP-1 drug: a multi-target drug might offer more weight loss, but they’d want to understand the fuller side-effect picture with their provider.<\/p>\n

What This Means for You Right Now<\/h3>\n

Retatrutide is investigational and not available. Mazdutide is approved only in China, not the US, so it isn’t available here either. Neither is offered by TrimRx. TrimRx provides currently available options, including compounded semaglutide and compounded tirzepatide (a dual agonist) plus brand injectables like Ozempic, Wegovy, Mounjaro, and Zepbound. If you want a multi-mechanism option that’s actually available, tirzepatide-based treatment is the approved dual-target choice today.<\/p>\n

Frequently Asked Questions<\/h3>\n

What’s the difference between a single, dual, and triple agonist?<\/h4>\n

A single agonist (like semaglutide) activates one receptor (GLP-1). A dual agonist activates two (tirzepatide hits GLP-1 and GIP; mazdutide hits GLP-1 and glucagon). A triple agonist (retatrutide) activates three (GIP, GLP-1, and glucagon). Generally, more targets have produced more weight loss.<\/p>\n

Does adding glucagon make weight-loss drugs more effective?<\/h4>\n

It appears to help by increasing calorie burning and reducing liver fat, on top of GLP-1’s appetite effects. Drugs with glucagon activity (like retatrutide and mazdutide) have produced strong weight loss, though glucagon can also raise heart rate, so it’s a balance.<\/p>\n

Are triple-agonist drugs available?<\/h4>\n

Retatrutide is investigational and not available. Mazdutide is approved in China but not by the FDA, so it’s unavailable in the US. TrimRx offers approved options including tirzepatide, a dual agonist, along with other GLP-1 medications.<\/p>\n

To focus on what you can actually start with today, you can explore the options available to you now<\/a> with a licensed provider.<\/p>\n

This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved, and mazdutide is not approved in the US; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

The newest weight-loss drugs work by hitting more hormone targets than GLP-1 alone, and the results suggest that more targets can mean more weight…<\/p>\n","protected":false},"author":7,"featured_media":55598,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-131090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=131090"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131090\/revisions"}],"predecessor-version":[{"id":131091,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131090\/revisions\/131091"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/55598"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=131090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=131090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=131090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}